

ERRATUM

Open Access



Erratum to: 'Phase II/III weekly *nab*-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

Denise A. Yardley^{1*}, Adam Brufsky², Robert E. Coleman³, Pierfranco F. Conte⁴, Javier Cortes⁵, Stefan Glück⁶, Jean-Mark A. Nabholz⁷, Joyce O'Shaughnessy⁸, Robert M. Beck⁶, Amy Ko⁶, Markus F. Renschler⁶, Debora Barton⁶ and Nadia Harbeck⁹

Unfortunately, the original version of this article [1] contained a few formatting errors which have been corrected via an update. In the eighth paragraph of the background there was an error. The original read as, "A phase II study evaluating the combination of nab-paclitaxel plus carboplatin as 199 first-line treatment for mTNBC is currently under way [31]." But should have read as "A phase II study evaluated the combination of nab-paclitaxel plus carboplatin a first-line treatment for mTNBC [31]."

Author details

¹Sarah Cannon Research Institute and the Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 100, Nashville, TN 37203, USA. ²University of Pittsburgh Medical Center, Pittsburgh, PA, USA. ³Weston Park Hospital, Sheffield Cancer Research Center, Sheffield, England. ⁴Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, and Istituto Oncologico Veneto IRCCS, Padova, Italy. ⁵Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. ⁶Celgene Corporation, Summit, NJ, USA. ⁷Centre de Lutte Contre le Cancer d'Auvergne, Clermont Ferrand, France. ⁸Texas Oncology-Baylor Charles A. Sammons Center; US Oncology, Dallas, TX, USA. ⁹Breast Center, University of Munich, Munich, Germany.

Published online: 03 February 2016

* Correspondence: dyardley@tnonc.com

¹Sarah Cannon Research Institute and the Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 100, Nashville, TN 37203, USA

Reference

1. Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, et al. Phase II/III weekly *nab*-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. *Trials*. 2015;16:575.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

